Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT ID: NCT05275439
Last Updated: 2025-02-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
106 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-03-17
Study Completion Date
2025-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03113643
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Blastic Plasmacytoid Dendritic Cell Neoplasm
RECRUITING
PHASE1
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748
Myelodysplastic Syndrome (MDS)
ACTIVE_NOT_RECRUITING
PHASE3
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
NCT05379166
Secondary Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome
ACTIVE_NOT_RECRUITING
PHASE2
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
NCT07153497
Acute Myeloid Leukemia
Myelodysplastic Syndrome
NOT_YET_RECRUITING
PHASE2
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
NCT05365035
Myelodysplastic Syndromes
Myeloproliferative Chronic Myelomonocytic Leukemia
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This Phase 1a/1b study is an open label, multicenter trial in subjects with higher-risk (i.e., intermediate, high or very high risk by IPSS-R) MDS or AML. The study is designed to evaluate the safety, PK, pharmacodynamic effects, and preliminary anti tumor activity of SL-172154 monotherapy and SL-1712154 administered with either Azacitidine or Azacitidine and Venetoclax. Subjects will receive SL-172154 as monotherapy or administered with Azacitidine with or without Venetoclax until documented disease progression, unacceptable toxicity or intolerance, withdrawal of consent, or the subject meets other criteria for discontinuation (whichever occurs first).
Part D: Safety and efficacy will be further explored in Part D. Approximately 60 subjects with previously untreated higher-risk MDS will be randomized equally into 3 groups: 3.0 mg/kg SL-172154+azacitidine, 1.0 mg/kg SL-172154+azacitidine and azacitidine monotherapy. Patients will be stratified based on the TP53 mutation status (TP53m vs TP53wt) and bone marrow blast count at study entry (\<5% vs ≥5%).
Part D: Safety and efficacy will be further explored in Part D. Approximately 60 subjects with previously untreated higher-risk MDS will be randomized equally into 3 groups: 3.0 mg/kg SL-172154+azacitidine, 1.0 mg/kg SL-172154+azacitidine and azacitidine monotherapy. Patients will be stratified based on the TP53 mutation status (TP53m vs TP53wt) and bone marrow blast count at study entry (\<5% vs ≥5%).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SL-172154
Patients will receive intravenous administration
Group Type
EXPERIMENTAL
SL-172154
Intervention Type
DRUG
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
SL-172154 + Azacitidine
Patients will receive intravenous administration of SL-172154 and Azacitidine.
Group Type
EXPERIMENTAL
SL-172154
Intervention Type
DRUG
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Azacitidine (AZA)
Intervention Type
DRUG
Chemotherapy drug approved for use in MDS and AML.
SL-172154 + Azacitidine + Venetoclax
Patients will receive intravenous administration of SL-172154 and Azacitidine plus oral venetoclax.
Group Type
EXPERIMENTAL
SL-172154
Intervention Type
DRUG
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Azacitidine (AZA)
Intervention Type
DRUG
Chemotherapy drug approved for use in MDS and AML.
Venetoclax
Intervention Type
DRUG
Drug approved for use in AML.
Part D-Previously untreated HR-MDS 1:1:1 Randomization
Patients will randomized to receive intravenous administration of the following:
* 3 mg/kg SL-172154 + Azacitidine
* 1 mg/kg SL-172154 + Azacitidine
* Azacitidine Monotherapy
Group Type
EXPERIMENTAL
SL-172154
Intervention Type
DRUG
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Azacitidine (AZA)
Intervention Type
DRUG
Chemotherapy drug approved for use in MDS and AML.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SL-172154
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Intervention Type
DRUG
Azacitidine (AZA)
Chemotherapy drug approved for use in MDS and AML.
Intervention Type
DRUG
Venetoclax
Drug approved for use in AML.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants are eligible to be included in the study only if all the following criteria apply.
1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.
2. Age ≥ 18 years.
3. For subjects with AML, confirmation of AML diagnosis by 2016 WHO criteria \[Arber, 2016\] (World Health Organization \[WHO\] classification, excluding acute promyelocytic leukemia \[APL\]).
4. Subjects with MDS must have:
1. morphologically confirmed diagnosis of MDS by 2016 WHO criteria \[Arber, 2016\] with \<20% blasts in bone marrow per bone marrow biopsy/aspirate or peripheral blood.
2. confirmation of intermediate, high or very high risk category by Revised International Prognostic Scoring System (IPSS-R).
Subjects with a diagnosis of any of the following are excluded: Atypical CML, juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), and unclassifiable MDS/ myeloproliferative neoplasm (MPN).
5. \[Dose Escalation Cohort - SL-172154 Monotherapy\] Subjects with AML must have relapsed/refractory disease (≥5% blasts by manual aspirate differential, flow cytometry, or immunohistochemistry) following at least 1 prior line of therapy but no more than 4 prior lines of therapy. Subjects with higher-risk MDS must have relapsed/refractory disease following at least 1 prior line but no more than 4 prior lines of therapy.
1. Prior hydroxyurea or other supportive care in the form of transfusions or growth factors will not be considered prior therapy.
2. Subjects who have undergone allogeneic-hematopoietic cell transplantation (HCT) are eligible if they are at least 6 months post-HCT, have relapsed AML or MDS as defined above, are not on treatment or prophylaxis for graft versus host disease (GVHD) for at least 6 weeks before administration of study treatment, and have no active GVHD.
3. Subjects must not be eligible for rescue chemotherapy and allogeneic-HCT per local or institutional guidelines at the time of screening.
6. \[Dose Escalation Cohort - SL-172154 Administered with Azacitidine\] Subjects with relapsed/refractory AML and MDS (as defined in Inclusion criterion 5) following at least 1 prior line of therapy but no more than 4 prior lines of therapy.
1. Treatment for MDS preceding secondary AML will not be considered as a prior line of therapy for secondary AML.
2. Prior hydroxyurea or other supportive care in the form of transfusions or growth factors will not be considered prior therapy.
3. Subjects who have undergone allogeneic-HCT are eligible if they are at least 6 months post-HCT, have relapsed AML or MDS as defined above, are not on treatment or prophylaxis for GVHD for at least 6 weeks before the first dose of study treatment, and have no active GVHD.
4. Subjects must not be eligible for rescue chemotherapy and allogeneic-HCT per local or institutional guidelines at the time of screening.
In addition, previously untreated subjects meeting either of the following criteria are eligible for this cohort:
1. Previously untreated subjects with AML with known adverse cytogenetics who fall into the adverse ELN risk group and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment.
2. Previously untreated subjects with MDS with documentation of at least one TP53 gene mutation or deletion based on a local test. Prior MDS therapy with lenalidomide or other supportive care in the form of transfusions or growth factors is allowed.
7. \[Dose Expansion Cohort Part A: SL-172154 Administered with Azacitidine\] Subjects diagnosed with MDS must be previously untreated. Prior MDS therapy with lenalidomide, luspatercept or supportive care in the form of transfusions or growth factors is allowed. Up to 1 cycle of prior therapy with a hypomethylating agent is permitted. Subjects with newly diagnosed treatment-related MDS are also eligible for enrollment.
8. \[Dose Escalation - Safety Run-in Cohort AND Dose Expansion Cohort Part B: SL 172154 Administered with Azacitidine and Venetoclax\] Subjects with AML must be previously untreated as defined by:
1. Subject must be ineligible for induction therapy with a standard cytarabine and anthracycline induction regimen due to age or co-morbidities as defined by the following:
* ≥ 75 years of age
* ≥ 60 to 74 years of age with at least one of the following co-morbidities:
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
* History of congestive heart failure (CHF) requiring treatment
* Ejection fraction ≤ 50%
* Chronic stable angina
* DLCO ≤ 65% or FEV1 ≤ 65%
* Creatinine clearance ≥ 30 mL/min to \< 45 mL/min
* Documented contraindication to anthracycline or cytarabine based therapy
2. Subjects with AML with known adverse cytogenetics who fall into the adverse ELN risk group and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are also eligible.
3. Subjects with newly diagnosed secondary AML and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are eligible for enrollment. Subjects with secondary AML after MDS must not have received prior chemotherapy or no more than 2 cycles of prior hypomethylating agent for MDS.
9. \[Dose Expansion Cohort Part C: SL-172154 Administered Azacitidine\]: Subjects with previously untreated de novo AML or secondary AML with TP53 gene mutation or deletion who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are eligible. All subjects must have documentation of at least one TP53 gene mutation/deletion based on local test. Subjects with secondary AML after MDS must not have received prior chemotherapy or no more than 2 cycles of prior hypomethylating agent for MDS.
10. ECOG Performance Status of 0, 1, or 2.
11. Laboratory values must meet the following criteria:
Laboratory parameter Threshold value White blood cell count (WBC) ≤ 20 x 109/L (Hydroxyurea is permitted to meet this criterion) Creatinine clearance (CrCl) ≥ 30 mL/min (using modified Cockcroft-Gault formula) ALT/AST ≤ 3 x ULN Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is \<35% and total bilirubin is ≤ 3.0 x ULN
12. Willing to provide consent for bone marrow aspirate samples at baseline and on-treatment for exploratory research as described in the Schedule of Assessments.
13. For subjects with relapsed/refractory disease, recovery from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade or controlled toxicities (e.g., alopecia) may be allowed upon agreement by the Medical Monitor)
14. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of the first dose of study treatment. NOTE: females are defined as being of childbearing potential unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally post-menopausal for at least 12 consecutive months. Documentation of post-menopausal status must be provided. To avoid pregnancy, FCBP must start using a highly effective method of contraception (i.e., \<1% failure rate) at least 14 days prior to initiation of study treatment and continue use during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of SL-172154, or for the duration required by local prescribing information after the last dose of azacitidine (i.e., for sites in UK and Spain, at least 6 months after the last dose of azacitidine in either combination regimen).
15. Male subjects with female partners must have azoospermia from a prior vasectomy, an underlying medical condition, or agree to use a highly effective method of contraception (i.e., \<1% failure rate) during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of SL-172154, or for the duration required by local prescribing information after the last dose of azacitidine (i.e., for sites in UK and Spain, at least 3 months; for sites in Canada, at least 6 months).
16. \[Dose Expansion Cohort Part D: SL-172154 with Azacitidine vs Azacitidine monotherapy\]: Subjects diagnosed with MDS must be previously untreated. Prior MDS therapy with lenalidomide, luspatercept or supportive care in the form of transfusions or growth factors is allowed. No prior therapy with a hypomethylating agent is permitted. Subjects with newly diagnosed treatment-related MDS are also eligible for enrollment. TP53 mutation status results based on local test must be available prior to randomization.
1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.
2. Age ≥ 18 years.
3. For subjects with AML, confirmation of AML diagnosis by 2016 WHO criteria \[Arber, 2016\] (World Health Organization \[WHO\] classification, excluding acute promyelocytic leukemia \[APL\]).
4. Subjects with MDS must have:
1. morphologically confirmed diagnosis of MDS by 2016 WHO criteria \[Arber, 2016\] with \<20% blasts in bone marrow per bone marrow biopsy/aspirate or peripheral blood.
2. confirmation of intermediate, high or very high risk category by Revised International Prognostic Scoring System (IPSS-R).
Subjects with a diagnosis of any of the following are excluded: Atypical CML, juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), and unclassifiable MDS/ myeloproliferative neoplasm (MPN).
5. \[Dose Escalation Cohort - SL-172154 Monotherapy\] Subjects with AML must have relapsed/refractory disease (≥5% blasts by manual aspirate differential, flow cytometry, or immunohistochemistry) following at least 1 prior line of therapy but no more than 4 prior lines of therapy. Subjects with higher-risk MDS must have relapsed/refractory disease following at least 1 prior line but no more than 4 prior lines of therapy.
1. Prior hydroxyurea or other supportive care in the form of transfusions or growth factors will not be considered prior therapy.
2. Subjects who have undergone allogeneic-hematopoietic cell transplantation (HCT) are eligible if they are at least 6 months post-HCT, have relapsed AML or MDS as defined above, are not on treatment or prophylaxis for graft versus host disease (GVHD) for at least 6 weeks before administration of study treatment, and have no active GVHD.
3. Subjects must not be eligible for rescue chemotherapy and allogeneic-HCT per local or institutional guidelines at the time of screening.
6. \[Dose Escalation Cohort - SL-172154 Administered with Azacitidine\] Subjects with relapsed/refractory AML and MDS (as defined in Inclusion criterion 5) following at least 1 prior line of therapy but no more than 4 prior lines of therapy.
1. Treatment for MDS preceding secondary AML will not be considered as a prior line of therapy for secondary AML.
2. Prior hydroxyurea or other supportive care in the form of transfusions or growth factors will not be considered prior therapy.
3. Subjects who have undergone allogeneic-HCT are eligible if they are at least 6 months post-HCT, have relapsed AML or MDS as defined above, are not on treatment or prophylaxis for GVHD for at least 6 weeks before the first dose of study treatment, and have no active GVHD.
4. Subjects must not be eligible for rescue chemotherapy and allogeneic-HCT per local or institutional guidelines at the time of screening.
In addition, previously untreated subjects meeting either of the following criteria are eligible for this cohort:
1. Previously untreated subjects with AML with known adverse cytogenetics who fall into the adverse ELN risk group and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment.
2. Previously untreated subjects with MDS with documentation of at least one TP53 gene mutation or deletion based on a local test. Prior MDS therapy with lenalidomide or other supportive care in the form of transfusions or growth factors is allowed.
7. \[Dose Expansion Cohort Part A: SL-172154 Administered with Azacitidine\] Subjects diagnosed with MDS must be previously untreated. Prior MDS therapy with lenalidomide, luspatercept or supportive care in the form of transfusions or growth factors is allowed. Up to 1 cycle of prior therapy with a hypomethylating agent is permitted. Subjects with newly diagnosed treatment-related MDS are also eligible for enrollment.
8. \[Dose Escalation - Safety Run-in Cohort AND Dose Expansion Cohort Part B: SL 172154 Administered with Azacitidine and Venetoclax\] Subjects with AML must be previously untreated as defined by:
1. Subject must be ineligible for induction therapy with a standard cytarabine and anthracycline induction regimen due to age or co-morbidities as defined by the following:
* ≥ 75 years of age
* ≥ 60 to 74 years of age with at least one of the following co-morbidities:
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
* History of congestive heart failure (CHF) requiring treatment
* Ejection fraction ≤ 50%
* Chronic stable angina
* DLCO ≤ 65% or FEV1 ≤ 65%
* Creatinine clearance ≥ 30 mL/min to \< 45 mL/min
* Documented contraindication to anthracycline or cytarabine based therapy
2. Subjects with AML with known adverse cytogenetics who fall into the adverse ELN risk group and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are also eligible.
3. Subjects with newly diagnosed secondary AML and who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are eligible for enrollment. Subjects with secondary AML after MDS must not have received prior chemotherapy or no more than 2 cycles of prior hypomethylating agent for MDS.
9. \[Dose Expansion Cohort Part C: SL-172154 Administered Azacitidine\]: Subjects with previously untreated de novo AML or secondary AML with TP53 gene mutation or deletion who are unlikely to benefit from standard intensive induction therapy or refuse intensive induction therapy at time of enrollment are eligible. All subjects must have documentation of at least one TP53 gene mutation/deletion based on local test. Subjects with secondary AML after MDS must not have received prior chemotherapy or no more than 2 cycles of prior hypomethylating agent for MDS.
10. ECOG Performance Status of 0, 1, or 2.
11. Laboratory values must meet the following criteria:
Laboratory parameter Threshold value White blood cell count (WBC) ≤ 20 x 109/L (Hydroxyurea is permitted to meet this criterion) Creatinine clearance (CrCl) ≥ 30 mL/min (using modified Cockcroft-Gault formula) ALT/AST ≤ 3 x ULN Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is \<35% and total bilirubin is ≤ 3.0 x ULN
12. Willing to provide consent for bone marrow aspirate samples at baseline and on-treatment for exploratory research as described in the Schedule of Assessments.
13. For subjects with relapsed/refractory disease, recovery from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade or controlled toxicities (e.g., alopecia) may be allowed upon agreement by the Medical Monitor)
14. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of the first dose of study treatment. NOTE: females are defined as being of childbearing potential unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally post-menopausal for at least 12 consecutive months. Documentation of post-menopausal status must be provided. To avoid pregnancy, FCBP must start using a highly effective method of contraception (i.e., \<1% failure rate) at least 14 days prior to initiation of study treatment and continue use during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of SL-172154, or for the duration required by local prescribing information after the last dose of azacitidine (i.e., for sites in UK and Spain, at least 6 months after the last dose of azacitidine in either combination regimen).
15. Male subjects with female partners must have azoospermia from a prior vasectomy, an underlying medical condition, or agree to use a highly effective method of contraception (i.e., \<1% failure rate) during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of SL-172154, or for the duration required by local prescribing information after the last dose of azacitidine (i.e., for sites in UK and Spain, at least 3 months; for sites in Canada, at least 6 months).
16. \[Dose Expansion Cohort Part D: SL-172154 with Azacitidine vs Azacitidine monotherapy\]: Subjects diagnosed with MDS must be previously untreated. Prior MDS therapy with lenalidomide, luspatercept or supportive care in the form of transfusions or growth factors is allowed. No prior therapy with a hypomethylating agent is permitted. Subjects with newly diagnosed treatment-related MDS are also eligible for enrollment. TP53 mutation status results based on local test must be available prior to randomization.
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
1. \[Monotherapy and Combination Regimen Dose Escalation Cohorts\] Prior treatment with:
* CAR-T cell therapy within 3 months from the first dose of the study drug.
* Prior treatment with anti-CD47 targeting agent or CD40 agonist within 28 days prior to the first dose of study treatment.
* Prior treatment with signal-regulatory protein alpha (SIRPα)-targeting agent.
* Other experimental therapies for AML or MDS within 14 days or at least 5 half-lives (whichever is shorter) prior to the first dose of study treatment.
2. Evidence of active CNS involvement with leukemia.
3. Subjects requiring agents other than hydroxyurea to control blast counts within 14 days prior to the first dose of study treatment.
4. Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
5. \[Only for Cohorts Including Venetoclax in the Regimen\] Subject has received strong and/or moderate CYP3A inducers within 7 days prior to the first dose of venetoclax.
6. Use of systemic corticosteroids (\>10 mg daily of prednisone or equivalent) or other non-steroidal immunosuppressive medication, current or within 14 days of the first dose of study treatment with the following exceptions (i.e., the following are allowed within 14 days of first dose):
* Topical, intranasal, inhaled, ocular, intraarticular corticosteroids
* Physiological doses of replacement steroid (e.g., for adrenal insufficiency)
* Steroid premedication for hypersensitivity reactions (e.g., reaction to IV contrast) or a brief course of treatment of non-autoimmune conditions (e.g., transfusion reactions, delayed-type hypersensitivity reaction caused by contact allergen).
7. Receipt of live attenuated vaccine within 30 days of first dose of SL-172154 treatment.
8. Subject has active, uncontrolled infection (e.g., viral, bacterial, or fungal). Subjects are eligible if infection is controlled with antibiotics, antivirals and/or antifungals.
9. \[Only for Cohorts Including Venetoclax in the Regimen\] Subject has a malabsorption syndrome or other condition that precludes the enteral route of administration.
10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal disease associated with diarrhea within 6 months of first dose of study treatment.
11. Clinically significant or uncontrolled cardiac disease including any of the following:
* Myocarditis
* Unstable angina within 6 months from first dose of study treatment
* Acute myocardial infarction within 6 months from first dose of study treatment
* Uncontrolled hypertension
* NYHA Class III or IV congestive heart failure
* Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular (AV) block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia not stabilized on therapy)
12. Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the Investigator would adversely affect his/her participation in the study.
13. Subjects who have had any major surgical procedure within 14 days of first dose of study treatment.
14. Subject is a woman who is pregnant or breast feeding or planning to become pregnant or breast feed while enrolled in this study.
15. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent.
16. Presence of another malignancy that requires active therapy and that in the opinion of the Investigator and Sponsor would interfere with the monitoring of disease assessments in this study.
17. Known hypersensitivity to any of the study medications including excipients of azacitidine.
18. Has undergone solid organ transplantation.
19. Known or active human immunodeficiency virus (HIV) infection
20. Known or active infection with hepatitis B (positive for hepatitis B surface antigen \[HbsAg\]) or hepatitis C virus (\[HCV\]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid \[RNA\]).
NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody \[HbcAb\]-positive but HbsAg-negative are eligible for enrollment. HCV: Subjects who are HCV Ab-positive but HCV RNA-negative are eligible for enrollment.
1. \[Monotherapy and Combination Regimen Dose Escalation Cohorts\] Prior treatment with:
* CAR-T cell therapy within 3 months from the first dose of the study drug.
* Prior treatment with anti-CD47 targeting agent or CD40 agonist within 28 days prior to the first dose of study treatment.
* Prior treatment with signal-regulatory protein alpha (SIRPα)-targeting agent.
* Other experimental therapies for AML or MDS within 14 days or at least 5 half-lives (whichever is shorter) prior to the first dose of study treatment.
2. Evidence of active CNS involvement with leukemia.
3. Subjects requiring agents other than hydroxyurea to control blast counts within 14 days prior to the first dose of study treatment.
4. Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
5. \[Only for Cohorts Including Venetoclax in the Regimen\] Subject has received strong and/or moderate CYP3A inducers within 7 days prior to the first dose of venetoclax.
6. Use of systemic corticosteroids (\>10 mg daily of prednisone or equivalent) or other non-steroidal immunosuppressive medication, current or within 14 days of the first dose of study treatment with the following exceptions (i.e., the following are allowed within 14 days of first dose):
* Topical, intranasal, inhaled, ocular, intraarticular corticosteroids
* Physiological doses of replacement steroid (e.g., for adrenal insufficiency)
* Steroid premedication for hypersensitivity reactions (e.g., reaction to IV contrast) or a brief course of treatment of non-autoimmune conditions (e.g., transfusion reactions, delayed-type hypersensitivity reaction caused by contact allergen).
7. Receipt of live attenuated vaccine within 30 days of first dose of SL-172154 treatment.
8. Subject has active, uncontrolled infection (e.g., viral, bacterial, or fungal). Subjects are eligible if infection is controlled with antibiotics, antivirals and/or antifungals.
9. \[Only for Cohorts Including Venetoclax in the Regimen\] Subject has a malabsorption syndrome or other condition that precludes the enteral route of administration.
10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal disease associated with diarrhea within 6 months of first dose of study treatment.
11. Clinically significant or uncontrolled cardiac disease including any of the following:
* Myocarditis
* Unstable angina within 6 months from first dose of study treatment
* Acute myocardial infarction within 6 months from first dose of study treatment
* Uncontrolled hypertension
* NYHA Class III or IV congestive heart failure
* Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular (AV) block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia not stabilized on therapy)
12. Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the Investigator would adversely affect his/her participation in the study.
13. Subjects who have had any major surgical procedure within 14 days of first dose of study treatment.
14. Subject is a woman who is pregnant or breast feeding or planning to become pregnant or breast feed while enrolled in this study.
15. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent.
16. Presence of another malignancy that requires active therapy and that in the opinion of the Investigator and Sponsor would interfere with the monitoring of disease assessments in this study.
17. Known hypersensitivity to any of the study medications including excipients of azacitidine.
18. Has undergone solid organ transplantation.
19. Known or active human immunodeficiency virus (HIV) infection
20. Known or active infection with hepatitis B (positive for hepatitis B surface antigen \[HbsAg\]) or hepatitis C virus (\[HCV\]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid \[RNA\]).
NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody \[HbcAb\]-positive but HbsAg-negative are eligible for enrollment. HCV: Subjects who are HCV Ab-positive but HCV RNA-negative are eligible for enrollment.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shattuck Labs, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shattuck Labs
Role: STUDY_DIRECTOR
Shattuck Labs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Site Status
UCLA Medical Center-Bowyer Oncology Center
Los Angeles, California, United States
Site Status
Yale Cancer Center
New Haven, Connecticut, United States
Site Status
Moffitt Cancer Center
Tampa, Florida, United States
Site Status
The University of Chicago
Chicago, Illinois, United States
Site Status
Norton Cancer Institute
Louisville, Kentucky, United States
Site Status
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site Status
University of Michigan
Ann Arbor, Michigan, United States
Site Status
START Midwest
Grand Rapids, Michigan, United States
Site Status
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Site Status
University of North Carolina, Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Site Status
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Site Status
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Site Status
Baylor Scott & White Research Institute
Dallas, Texas, United States
Site Status
MD Anderson Cancer Center
Houston, Texas, United States
Site Status
VCU Massey Cancer Center
Richmond, Virginia, United States
Site Status
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Site Status
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Site Status
Jewish General Hospital
Montreal, Quebec, Canada
Site Status
King's College Hospital NHS Foundation Trust
London, Denmark Hill, United Kingdom
Site Status
University Hospitals Plymouth NHS Trust, Derriford Hospital
Crownhill, Plymouth, United Kingdom
Site Status
Imperial College Healthcare NHS Trust
London, , United Kingdom
Site Status
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SL03-OHD-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
TERMINATED
PHASE3
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318
WITHDRAWN
PHASE1/PHASE2
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
NCT03466294
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523
ACTIVE_NOT_RECRUITING
PHASE3
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
NCT04817241
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT01305499
ACTIVE_NOT_RECRUITING
PHASE2
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
NCT05226455
RECRUITING
PHASE1/PHASE2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
RECRUITING
PHASE2
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT01038635
COMPLETED
PHASE1/PHASE2
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
NCT04161885
TERMINATED
PHASE3
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
NCT01048034
COMPLETED
PHASE2
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NCT03718143
TERMINATED
PHASE2
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
NCT05766514
WITHDRAWN
PHASE2
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT04550442
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
NCT05155709
TERMINATED
PHASE1
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
NCT02575963
COMPLETED
PHASE1/PHASE2
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT02775903
COMPLETED
PHASE2
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
NCT04842604
COMPLETED
PHASE3
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT03306264
COMPLETED
PHASE3
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
NCT01814826
COMPLETED
PHASE1
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
NCT02719574
COMPLETED
PHASE1/PHASE2
A Phase II Study of Maintenance With Azacitidine in MDS Patients
NCT00446303
TERMINATED
PHASE2
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
NCT03573024
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
NCT06773208
RECRUITING
PHASE2
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
NCT03326310
RECRUITING
PHASE1